LPS-Toll-Like Receptor-Mediated Signaling on Expression of Protein S and C4b-Binding Protein in the Liver.
Protein S (PS), mainly synthesized in hepatocytes and endothelial cells, plays a critical role as a cofactor of anticoagulant activated protein C (APC). PS activity is regulated by C4b-binding protein (C4BP), structurally composed of seven α-chains (C4BPα) and a β-chain (C4BPβ). In this paper, based primarily on our previous studies, we review the lipopolysaccharide (LPS)-induced signaling which affects expression of PS and C4BP in the liver. Our in vivo studies in rats showed that after LPS injection, plasma PS levels are significantly decreased, whereas plasma C4BP levels first are transiently decreased after 2 to 12 hours and then significantly increased after 24 hours. LPS decreases PS antigen and mRNA levels in both hepatocytes and sinusoidal endothelial cells (SECs), and decreases C4BP antigen and both C4BPα and C4BPβ mRNA levels in hepatocytes. Antirat CD14 and antirat Toll-like receptor (TLR)-4 antibodies inhibited LPS-induced NFκB activation in both hepatocytes and SECs. Furthermore, inhibitors of NFκB and MEK recovered the LPS-induced decreased expression of PS in both cell types and the LPS-induced decreased expression of C4BP in hepatocytes. These data suggest that the LPS-induced decrease in PS expression in hepatocytes and SECs and LPS-induced decrease in C4BP expression in hepatocytes are mediated by MEK/ERK signaling and NFκB activation and that membrane-bound CD14 and TLR-4 are involved in this mechanism.
Hayashi
Tatsuya
T
Department of Molecular Pathobiology, Mie University Graduate School of Medicine, Tsu-city, Mie 514-8507, Japan.
Suzuki
Koji
K
J Biol Chem. 1993 Feb 5;268(4):2872-7
8428962
Infect Immun. 2002 Jul;70(7):3433-42
12065483
Immunol Res. 2007;39(1-3):249-60
17917069
Br J Haematol. 1990 May;75(1):112-7
2142890
Blood. 1986 Oct;68(4):881-5
2944555
J Clin Invest. 1984 Dec;74(6):2082-8
6239877
J Biol Chem. 1986 Sep 15;261(26):12022-7
2943733
Blood. 1986 Jan;67(1):64-70
3000483
J Clin Invest. 1988 May;81(5):1445-54
3284913
J Biol Chem. 1981 Nov 10;256(21):11128-31
6457049
J Biol Chem. 1996 Aug 23;271(34):20861-7
8702842
Thromb Res. 1996 Feb 1;81(3):307-14
8928088
J Biol Chem. 2000 Apr 14;275(15):11058-63
10753909
Proc Natl Acad Sci U S A. 1981 Apr;78(4):2512-6
6454142
Blood. 1986 Feb;67(2):406-10
2935209
J Biochem. 1995 Feb;117(2):374-83
7608128
J Biol Chem. 1990 Jun 5;265(16):9072-6
2140568
Biochemistry. 1980 Feb 5;19(3):401-10
7356933
Blood. 1985 Dec;66(6):1452-5
2933098
J Biol Chem. 1988 Sep 5;263(25):12759-64
2970465
Thromb Haemost. 1991 Feb 12;65(2):126-9
1828915
Thromb Haemost. 2007 Sep;98(3):543-56
17849042
Eur J Biochem. 1993 Nov 1;217(3):857-65
8223642
Thromb Haemost. 1995 May;73(5):819-24
7482409
Blood. 1986 Apr;67(4):1168-71
2937470
Arterioscler Thromb Vasc Biol. 2006 Sep;26(9):2168-74
16840717
Blood. 1994 Jul 15;84(2):483-9
8025276
J Thromb Haemost. 2006 Aug;4(8):1763-73
16879219
Thromb Haemost. 1996 Nov;76(5):729-34
8950781
Circulation. 2003 Apr 8;107(13):1791-6
12665496
Semin Thromb Hemost. 2000;26(5):571-87
11129414
Biochem J. 1983 Mar 1;209(3):847-56
6223625
J Biol Chem. 2000 Jul 7;275(27):20861-6
10877845
Proc Natl Acad Sci U S A. 1983 Jun;80(11):3461-5
6222381
Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2728-32
8146182
Nat Immunol. 2003 Jan;4(1):87-91
12447359
Immunopharmacology. 1995 Apr;29(3):187-205
7542643
J Thromb Haemost. 2008 Nov;6(11):1858-67
18752574
Thromb Res. 1990 Nov 1;60(3):237-40
2150729
Thromb Haemost. 1991 Jul 12;66(1):49-61
1833851
Thromb Haemost. 1997 Jun;77(6):1201-14
9241758
Biochem Med Metab Biol. 1991 Jun;45(3):350-4
2049187